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Pediatrics, Ludwig-Maximilians University, Munich 80337, GermanyNew treatments to overcome the obstacles of conventional anti-
cancer therapy are a permanent subject of investigation. One
promising approach is the application of toxins linked to
cell-speciﬁc ligands, so-called immunotoxins. Another attrac-
tive option is the employment of toxin-encoding plasmids.
However, immunotoxins cause hepatoxicity, and DNA thera-
peutics, among other disadvantages, bear the risk of insertional
mutagenesis. As an alternative, this study examined chemically
modiﬁed mRNAs coding for diphtheria toxin, subtilase cyto-
toxin, and abrin-a for their ability to reduce cancer cell growth
both in vitro and in vivo. The plant toxin abrin-a was the most
promising candidate among the three tested toxins and was
further investigated. Its expression was demonstrated by west-
ern blot. Experiments with ﬁreﬂy luciferase in reticulocyte ly-
sates and co-transfection experiments with EGFP demon-
strated the capability of abrin-a to inhibit protein synthesis.
Its cytotoxic effect was quantiﬁed employing viability
assays and propidium iodide staining. By studying caspase-
3/7 activation, Annexin V-binding, and chromatin condensa-
tion with Hoechst33258 staining, apoptotic cell death could
be conﬁrmed. In mice, repeated intratumoral injections of
complexed abrin-a mRNA resulted in a signiﬁcant reduction
(89%) of KB tumor size compared to a non-translatable control
mRNA.Received 23 April 2017; accepted 20 December 2017;
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Conventional anti-cancer therapy is often limited by chemoresist-
ance,1 radiation resistance,2 and severe side effects like cardiotoxicity3
or neurocognitive deﬁcits.4 Therefore, the need for innovative cancer
therapeutic options is immense. For instance, administration of im-
munotoxins as anti-cancer therapeutics is being tested in clinical
studies,5 with one drug gaining FDA approval.6 Immunotoxins are
cell-speciﬁc ligands linked either to plant or to bacterial toxins, lead-
ing to a selective killing of target cells.7,8 The advantage of this
approach, compared to other tumor treatments, is high tumor spec-
iﬁcity and hence less damage of healthy tissue. A further beneﬁt is
their applicability to both solid and non-solid tumors.9 Still, despite
their cell speciﬁc toxicity in vitro, in some cases damage to healthy tis-
sue, particularly to the liver, has been observed.10,11 Another disad-Molecular Therapy: Methods &
This is an open access article under the CC BY-NC-vantage is the comparatively slow protein uptake from blood vessels
by tumors due to their abnormal tissue architecture.11
An alternative that might avoid these deﬁciencies but shares many of
the beneﬁts of immunotoxins is the employment of nucleic acids cod-
ing for toxic proteins as suicide cancer therapy. Hochberg and co-
workers12,13 have shown the potential of this approach by applying
a plasmid coding for diphtheria toxin. Expression of diphtheria toxin
is under the control of H19 promoter, which is highly active in a range
of human cancers, ensuring that toxin production is conﬁned to the
tumor. Clinical trials (phase 2b) with this plasmid-based approach
have been successful.12 Analogously, tumor growth was reduced after
intratumoral delivery of a recombinant adeno-associated virus con-
taining DNA coding for the toxin trichosanthin.14 Nevertheless,
DNA-based gene therapeutics bear some risks and disadvantages,
with potential genomic integration followed by mutation being one
of the most important safety concerns.15 The employment of
messenger RNA instead of DNA is an attractive approach to circum-
vent several deﬁciencies of plasmid-based transfection. The most
important beneﬁts of mRNA application versus DNA therapeutics
are (1) no risk of insertional mutagenesis,15 (2) no need to enter the
nucleus, therefore resulting in higher transfection efﬁciency and
earlier onset of protein expression,16 (3) expression being self-limited
because of short mRNA half-life,17,18 and (4) only the sequence of in-
terest being introduced into the cell.16 Also, using the herpes simplex
virus-thymidine kinase/ganciclovir (TK/GCV) suicide gene therapy
system, Wang et al.19 observed that the reduction in tumor growth
was signiﬁcantly higher for mRNA than for plasmid DNA (pDNA).
In spite of the advantages of mRNA over pDNA as therapeutic agent,
its presumably low stability and high immunogenicity prevented its
broad application until the last decade. Since Wolff et al.20 showed
the ﬁrst successful mRNA transfection in vivo in 1990, research has
identiﬁed ways to evade these issues. Several studies have reported
increased stability and decreased immunogenicity after incorporatingClinical Development Vol. 8 March 2018 ª 2018 The Authors. 141
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Comparison of the Decrease in Cell Viability Caused by SubA,
DTA, and AA cmRNA in HuH7 and KB Cells
Forty-eight hours post-transfection of KB and HuH7 cells with either of the cmRNAs
SubA (subtilase cytotoxin, A-chain), DTA (diphtheria toxin, A-chain), AA (abrin-a,
A-chain), or one of their stop cmRNAs, cell viability was assessed by quantifying
the ATP content using the CellTiter-Glo Luminescence Viability Assay. Cell viability
was proportional to the measured luminescence. 100 ng cmRNA were applied.
Data are presented as mean in % ± SEM of cells transfected with the respective
stop cmRNA (dotted line). Statistical significance for HuH7 and KB cells versus
cells transfected with the respective stop cmRNA was assessed by Kruskal-Wallis
test adjusted for multiple comparisons, with *p < 0.05, **p < 0.01, ***p < 0.001, and
n = 3.
Molecular Therapy: Methods & Clinical Developmentmodiﬁed nucleotides in in vitro transcribed mRNAs.21–25 Accord-
ingly, in the present study, chemically modiﬁed mRNA (cmRNA)
comprising 50-methylcytosine and 20-thiouridine, which was shown
previously to result in stabilized non-immunogenic mRNA,24 was
applied.
In this study, we combine the advantages of immunotoxins and
mRNA-based therapeutics. We investigated the cytotoxic potential
of mRNA transcripts coding for three toxins that have been previ-
ously used as immunotoxins.9,26–28 Diphtheria toxin, produced by
Corynebacterium diphtheria,29 subtilase cytotoxin, produced by shiga
toxigenic Escherichia coli (STEC),30 and the plant-derived abrin-a,
isolated from Abrus precatorius,31 all belong to the family of conven-
tional AB-toxins.30,32,33 After binding of the B-subunit to the target
cell, the catalytic A-subunit of AB-toxins enters the cell34 and medi-
ates the toxic effects via impairment of protein synthesis, resulting in
cell death.35–37 We focused on these three toxins since they represent
different signaling pathways of protein synthesis inhibition and have
shown promising anti-tumor effects in pre-clinical or clinical
studies.26,28,38
In a ﬁrst step, we compared the three cmRNAs regarding their po-
tency to inhibit cell viability in two different tumor cell lines. The142 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchbest-performer abrin-a, A-chain (AA) cmRNA was then investigated
in detail to estimate its potential as new anti-tumor agent. In order to
exclude any possible unspeciﬁc effects of mRNA transfection, a
cmRNA (AAstop) was utilized that shows no translation. This was
achieved by scrambling the Kozak element39 and mutating the start
as well as all in frame downstreamATGs into TAGs. In in vitro exper-
iments, the expression of AA was veriﬁed by western blot, and it was
assessed for its capacity to decrease protein synthesis, its cytotoxicity,
and the apoptotic characteristics of induced cell death. In vivo, exper-
iments in mice showed that intratumoral injection of AA cmRNA re-
sulted in a signiﬁcantly reduced tumor growth.
This is a ﬁrst proof-of-concept study demonstrating the efﬁcacy of
“killer RNAs” as promising anti-tumor agents. Further studies with
different tumor models will be highly valuable in determining the
true potential of such mRNA-based therapeutics.RESULTS
Comparison of the Decrease in Cell Viability Caused by SubA,
DTA, and AA cmRNA in HuH7 and KB Cells
To determine the effectivity of the different cmRNAs, namely subti-
lase cytotoxin, A-chain (SubA), diphtheria toxin, A chain (DTA),
and AA, cell viability measurements using the human cervix carci-
noma cell line KB and the human hepatocarcinoma cell line HuH7
were performed. As control, stop cmRNAs were designed by intro-
ducing small changes in the sequence of the toxins that prevent trans-
lation. Cells were transfected with 100 ng of cmRNA. At 48 hr after
transfection, cell viability was assessed by measuring the ATP content
using the CellTiter-Glo Luminescence Viability Assay (Figure 1). In
HuH7 cells, all three toxins induced a signiﬁcant reduction in cell
viability of 65%–70% (SubA, p = 0.0127; DTA, p = 0.0494; AA, p =
0.0017) in comparison to cells transfected with the respective stop
cmRNA. In KB cells, the decrease in cell viability by SubA cmRNA
was low with 32%, whereas DTA cmRNA and AA cmRNA decreased
cell viability signiﬁcantly by almost 60% compared to cells transfected
with the respective stop cmRNA (SubA, p = 0.2144; DTA, p = 0.0009;
AA, p = 0.0002). Considering the different size of the two RNAs (AA,
1.0 kb, versus DTA, 0.8 kb), more DTA molecules were required to
induce similar effects on cell viability compared to AA. This led to
the conclusion that AA was the most potent toxin and was therefore
used in the following experiments with KB cells.Detection of Abrin-a Protein after Transfection of KB Cells with
AA cmRNA by Western Blot
The expression of abrin-a after transfection of KB cells with AA
cmRNA was veriﬁed by western blot analysis. For this, KB cells
were transfected with 40 ng and 80 ng AA or AAstop cmRNA, lysed
24 hr post-transfection, and SDS-PAGE and western blot was per-
formed. Figure 2 clearly demonstrates abrin-a protein production
in KB cells after transfection with AA cmRNA in a concentration-
dependent manner. After transfection with AAstop cmRNA and in
case of untransfected control cells (UTs), no abrin-a protein was
detected.2018
Figure 2. Detection of Abrin-a Protein after Transfection of KBCells with AA
cmRNA by Western Blot
KB cells were transfected with 40 or 80 ng of AA (abrin-a, A-chain) or AAstop
cmRNA. Twenty-four hours post-transfection, cells were lysed and SDS-PAGE and
western blot was performed. Anti-vinculin antibody was used as loading control.
A representative blot, including untransfected control cells (UT), is shown. n = 2.
www.moleculartherapy.orgInhibition of Protein Synthesis by AA cmRNA
The capability of AA to inhibit protein synthesis was assessed by co-
treatment of rabbit reticulocyte lysate with 1 mg ﬁreﬂy luciferase (luc)
cmRNA and co-transfection of KB cells with 50 ng EGFP cmRNA.
Forty-ﬁve minutes after treatment of lysate with 0.1 mg AA cmRNA,
luminescence was reduced signiﬁcantly (p = 0.0079 in comparison to
AAstop cmRNA) to 0.1% in comparison to lysate treated with luc
cmRNA only (luc control, Figure 3A). Addition of AAstop cmRNA,
however, did not result in decreased luc activity. KB cells transfected
with AA cmRNA showed considerable EGFP ﬂuorescence at
0.0005 ng, but no EGFP ﬂuorescence was visible at 0.05 or 5 ng after
24 hr (Figure 3B). EGFP ﬂuorescence in cells transfected with AAstop
cmRNA was not affected at any of the tested concentrations. These
microscopic observations were further conﬁrmed by ﬂow cytometry
analysis, showing both the mean ﬂuorescence intensity (MFI) of
EGFP (Figure 3C) and the percentage of EGFP-positive cells (Fig-
ure 3D). Compared to cells transfected with EGFP cmRNA only
(EGFP control), the MFI of EGFP was unchanged at 0.0005 ng AA
cmRNA. At 0.05 and 5 ng AA cmRNA, the MFI of EGFP was
decreased to 3.4% and 1.7%, respectively, compared to EGFP control
cells. Similar to the results obtained with MFI, the number of EGFP-
positive cells was unchanged at 0.0005 ng AA cmRNA (compared to
EGFP control), but reduced by 77% at 0.05 ng or 100% at 5 ng. The
differences between AA and AAstop cmRNA were signiﬁcant for
0.05 and 5 ng (p < 0.0001). These results demonstrate that production
of abrin-a after treatment of reticulocyte lysate or of KB cells with AA
cmRNA was active and led to inhibition of protein synthesis of co-
applied luc or EGFP cmRNA.
Toxicity of AA cmRNA on KB Cells
The toxic effect of AA cmRNA on KB cells in comparison to AAstop
cmRNAwas evident in microscopic images taken 48 hr after transfec-
tion (Figure 4A). Cell viability measurements (Figure 4B) showed
reduction at all tested concentrations of AA cmRNA compared to
UTs. Toxicity at 10 ng was low with 9.2% decrease in viability but
increased considerably at 50 ng and 100 ng with 60.2% and 77.6%
reduction of cell viability compared to UT cells. The percentage of
dead cells, determined by staining with propidium iodide (PI), was
in agreement with these ﬁndings. At 10 ng AA cmRNA, the numberMoleculof PI-positive cells was twice as high as for UT. For 50 and 100 ng, the
percentage of dead cells increased to 45%–51% of all cells. With the
exception of PI staining at 10 ng dose, the differences between AA
and AAstop cmRNA were statistically signiﬁcant (10 ng, p =
0.0002; others, p < 0.0001). It could be shown that AA cmRNA not
only distinctly decreases cell viability but also induces cell death.
ApoptoticCell Death after TransfectingKBCellswith AA cmRNA
The occurrence of apoptotic cell death after transfection with AA
cmRNA was demonstrated by investigating Annexin V-binding,
caspases-3 and -7 activity, and chromatin condensation using
Hoechst33258 staining. At 24 hr after transfection with 10 ng AA
cmRNA, binding of Annexin V to the cell membrane increased
compared to UTs (Figure 5A). The fraction of cells that were
Annexin V positive but PI negative was 27% for 50 ng and 41% for
100 ng dose group compared to UT with 3.4%. The increase of
apoptotic cells after transfection with AA cmRNA was dose depen-
dent. Figure 5B shows a representative dot plot of the Annexin V-PI
ﬂuorescence cytometry assay. In comparison to AAstop cmRNA, a
clear shift from viable cells (double negative) to apoptotic (Annexin
V positive, PI negative) and dead cells (double positive) was detectable
for AA cmRNA-transfected cells. Twenty-four hours after transfec-
tion, an increase in caspase-3 and -7 activity could be observed at
10 ng (Figure 5C). For 50 and 100 ng doses groups, the activity of cas-
pases-3 and -7 was ﬁve times higher for AA cmRNA than for UT.
Forty-eight hours post-transfection with AA cmRNA, the apoptotic
characteristics “membrane blebbing” and nuclear fragmentation
could be observed (Figure 5D) as well as shrinkage and rounding of
cells (Figure 4A) In Figure 5E, the Hoechst33258-positive cells were
quantiﬁed. The increase in apoptotic cells was low compared to UT
for 10 ng AA cmRNA. The number of apoptotic cells in case of AA
cmRNA was three times higher than for UT at 50 and 100 ng. As
observed for caspase-3 and -7 activity, no major difference in degree
of apoptosis could be detected for AA cmRNA transfections with 50
or 100 ng. AAstop cmRNA did not show any induction of apoptotic
cell death or morphological aberrations under the tested conditions.
For all tested doses, concerning 10 ng only for caspase-3 and -7 activ-
ity, increase in apoptosis was statistically signiﬁcant for AA compared
to AAstop cmRNA (10 ng, p = 0.0075; others, p < 0.0001). Taken
together, the results suggest that transfection of KB cells with AA
cmRNA leads to predominantly apoptotic cell death.
Decrease in Cell Viability by AA-LF132 In Vitro and Inhibition of
Tumor Growth In Vivo
Prior to performing the in vivo experiment, the Ethris’ proprietary
cationic lipid formulation LF132 was tested in vitro on KB cells for
its effectiveness. Forty-eight hours after transfection, very high
toxicity of AA-LF132 but no toxic effect of AAstop-LF132 or 2% su-
crose (vehicle control) was observed (Figure 6A). This was further
conﬁrmed by assessing cell viability (Figure 6B). For 10, 50, or
100 ng AA cmRNA, cell viability was reduced by 56%, 99%, or
100% compared to UTs, respectively. Accordingly, in comparison
to AA-Lipofectamine 2000 (cf. Figure 4B), potency of inducing
toxicity of AA-LF132 was considerably higher. AAstop-LF132 alsoar Therapy: Methods & Clinical Development Vol. 8 March 2018 143
Figure 3. Inhibition of Protein Synthesis by AA cmRNA
(A) Inhibition of translation of firefly luciferase (luc) cmRNA in a rabbit reticulocyte lysate system by AA cmRNA. Rabbit reticulocyte lysate was treated with 1 mg luc cmRNA and
0.1 mg AA (abrin-a, A-chain) or AAstop cmRNA and luminescence as ameasure of luc activity was determined 45min after start of the reaction. Data are presented asmean in
% ±SEMof lysate treated only with luc cmRNA (luc ctrl, dotted line). Statistical significance versus AAstop cmRNAwas assessed byMann-Whitney U test, with **p < 0.01 and
n = 3. (B–D) Inhibition of EGFP fluorescence in KB cells by AA cmRNA. KB cells were co-transfected with 50 ng EGFP cmRNA and either AA (abrin-a, A-chain) or AAstop
cmRNA. Twenty-four hours post-transfection, inhibition of protein synthesis was assessed by fluorescence microscopy (B) and flow cytometry (C and D). Representative
fluorescence images are shown (B). Mean fluorescence intensity (MFI) (C) and percentage of EGFP-positive cells (D) are depicted. Data are presented asmean in% ± SEM of
control cells transfected only with EGFP cmRNA (EGFP ctrl, dotted line). Statistical significance versus AAstop cmRNA was assessed by two-way ANOVA adjusted for
multiple comparisons, with ****p < 0.0001 and n = 3.
Molecular Therapy: Methods & Clinical Developmentshowed some toxicity at higher concentrations, but far less compared
to AA-LF132. The reduction in luminescence by AA-LF132 was sta-
tistically signiﬁcant in comparison to AAstop-LF132 for all tested
doses (p < 0.0001).
To test the anti-tumor activity of AA-LF132 in vivo, 5  106 KB cells
were injected into the ﬂank of immuno-deﬁcient Naval Medical
Research Institute-nude (NMRI-nu) mice. In a small pre-experiment,
the expression characteristics of intratumorally injected RNA were
investigated. Therefore, 10 mg lipid nanoparticle formulated cmRNA
coding for ﬁreﬂy luciferase was injected three times. Twenty-four
hours after the third application, considerable and locally deﬁned
luciferase activity was observed (Figure 6C). In the main experiment,
the complexed cmRNAs or 2% sucrose were injected intratumorally
as soon as the tumors reached a sufﬁcient size (100mm3). The treat-
ment was repeated three times in 2- to 5-day intervals. Surveillance of
general condition and body weight during treatment as well as exam-
ination of blood parameters (white blood cells, red blood cells, hemo-
globin, hematocrit, and platelets) on day 21 after injection of tumor144 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchcells showed no disparities between the three groups (data not
shown). However, while the formation of cutaneous lesions up to ul-
cers was not observed in AAstop-LF132 or 2% sucrose-treated mice, it
was present in all but one animal of the AA-LF132 group. Measure-
ment of the tumor volume throughout the treatment demonstrated a
marked difference in growth rate between the different groups (Fig-
ure 6D). Twelve days after the ﬁrst injection, tumor volume was deter-
mined ex vivo (Figure 6E). It was shown that treatment resulted in a
signiﬁcantly lower tumor size for AA-LF132 than for AAstop-LF132
(p = 0.0010) or for 2% sucrose (p = 0.0350). With a mean volume of
50 mm3, AA-LF132 treated tumors were 89% smaller than tumors in-
jected with AAstop-LF132. The difference in tumor size concerning
AAstop-LF132 and 2% sucrose was statistically not signiﬁcant. This
experiment clearly demonstrates the potential of cmRNA coding
for toxic proteins to reduce tumor growth in vivo.
DISCUSSION
Employment of mRNA coding for different cellular and viral proteins
for anti-cancer therapies has been investigated in previous studies.2018
Figure 4. Toxicity of AA cmRNA on KB Cells
Forty-eight hours post-transfection of KB cells with AA (abrin-a, A-chain) or AAstop
cmRNA. (A) Representative pictures were taken of cells transfected with 100 ng
cmRNA or of untransfected cells (UT). (B) Cell viability was determined bymeasuring
ATP content with the CellTiter-Glo Luminescence Viability Assay. Cell viability was
proportional to themeasured luminescence. Data is presented asmean in% ± SEM
of untransfected control cells (UT, dotted line). (C) Number of dead cells was
counted using propodium iodide (PI) staining and flow cytometry analysis. Per-
centage of PI-positive cells was compared to untransfected control cells (UT, dotted
line) and is shown as mean in % ± SEM. Statistical significance versus AAstop
cmRNA was assessed by two-way ANOVA adjusted for multiple comparisons, with
***p < 0.001, ****p < 0.0001, and n = 3.
www.moleculartherapy.orgVan der Jeught et al.,40 for instance, deliveredmRNA coding for inter-
feron b fused to the transforming growth factor b (TGF-b) receptor II
intratumorally to enhance tumor-speciﬁc immunity. Also, an mRNA
encoding the TK/GCV suicide system was applied intravenously to
suppress tumor growth.19 In both studies, reduction of tumor growth
was observed. The present study aimed to investigate whether protein
toxins are suitable for employment as mRNA cancer therapeutics.
For this purpose, cmRNAs coding for the catalytic A-chain of three
AB-toxins, namely subtilase cytotoxin (SubA), diphtheria toxin
(DTA) and abrin-a (AA), were employed.
A cell viability assay performed on the cancer cell lines HuH7 and KB
revealed AA as the most promising candidate for further investiga-
tion. Concerning HuH7 cells, the decline in viability 48 hr after
transfection was comparably high for all three toxins. While AA
and DTA cmRNA showed a similar effect on KB cells, SubA cmRNAMoleculshowed reduced toxicity compared to HuH7 cells. Because of differ-
ences in cell number and cell size, a direct comparison between the
two cell lines regarding their sensitivity to toxin mediated cell death
is limited. As DTA inactivates EF-2 by ADP-ribosylation29,35 and
AA blocks the binding of EF-2 to the ribosome by cleaving an
adenine from the rRNA,41 the two toxins show a similar and irre-
versible mode of action. The activation of unfolded protein response
(UPR), as cause for cell death by SubA,36 distinguishes it clearly from
the other toxins. As the induction of the UPR also increases the
expression of GRP78,42 the substrate of SubA,36 it seems possible
that UPR-induced apoptosis can be evaded. This might account
for the cell-dependent differences in effectiveness observed when
comparing SubA with DTA and AA. As the molecular weight of
AA compared to DTA cmRNA is higher (AA, 1.0 kb, versus DTA,
0.8 kb), AA was more effective than DTA when considering molec-
ular toxicity. As one challenge of successful mRNA-based therapy is
transfection efﬁciency, high effectivity per mRNA molecule is desir-
able. Moreover, with high molecular toxicity, comparably lower
doses of AA are sufﬁcient, thereby reducing potential toxic side ef-
fects of mRNA delivery.
To ensure that the various effects caused by transfection of AA were
speciﬁc, a control cmRNA (AAstop) was applied in this study.
AAstop displays the same sequence as AA but has a scrambled
Kozak39 element, and the start as well as all in-frame downstream
ATGs mutated to TAGs. Prior to translation, the 40 S ribosome scans
the mRNA sequence, starting at the 50 end, and initiates translation
when it reaches the ﬁrst AUG codon.39 Binding to this ﬁrst AUG
by the ribosome is strongly supported by a consensus sequence
(Kozak element) directly upstream. Consequently, as could be as-
serted in this study, the introduced alterations in AAstop cmRNA
prevented its translation.
The successful expression of abrin-a protein after transfection of KB
cells with AA cmRNA was demonstrated by western blot analysis. At
the lower dose of 40 ng cmRNA, protein production was reduced
compared to 80 ng cmRNA.
A rabbit reticulocyte lysate system assessed that AA almost
completely inhibits protein synthesis of co-applied luc cmRNA.
Moreover, ﬂuorescence inhibition of co-transfected EGFP cmRNA
conﬁrmed that transfected AA cmRNA was translated into an active
toxin. For 0.05 ng dose, only one-fourth of transfected cells were
EGFP positive with a weak EGFP signal (low MFI). In those cells,
the comparably low amount of AA presumably was not able to inac-
tivate all ribosomes before enough EGFP molecules for ﬂuorescence
detection had been synthesized. In contrast, none of the cells trans-
fected with 5 ng AA cmRNA showed detectable EGFP ﬂuorescence.
This dose dependency of translational inhibition by abrin has been
shown before.43 The results demonstrate that AA exerts its inﬂuence
shortly after the start of translation. As AA directly inhibits protein
synthesis by cleaving an adenine from the 28 S rRNA,41 thereby
immediately blocking translation, such immediate effects on transla-
tion are conceivable. Also, Hung et al.44 detected depurination ofar Therapy: Methods & Clinical Development Vol. 8 March 2018 145
Figure 5. Apoptotic Cell Death after Transfecting KB Cells with AA cmRNA
At 24 hr (A–C) or 48 hr (D and E) post-transfection of KB cells with AA (abrin-a, A-chain) or AAstop cmRNA, cells were examined for apoptosis. (A and B) Annexin V-AF488 and
propidium iodide (PI) double staining flow cytometry assay. (A) Percentages of cells in early apoptotic stage (Annexin V-AF488 positive, PI negative). Data is shown asmean in
% ± SEM and is compared to untransfected control cells (UT, dotted line). (B) Representative dot plots of cells transfected with 100 ng cmRNA. The percentages of the
different populations are given in the respective corners. (C) Caspase-Glo 3/7 assay; activity was proportional to luminescence. Data is represented as mean in % ± SEM of
untransfected control cells (UT, dotted line). (D and E) Hoechst33258 staining. (D) Representative phase contrast and fluorescence images of cells transfected with 100 ng
cmRNA are displayed. Arrows depict cells showing “membrane blebbing” or nuclear fragmentation. (E) Number of Hoechst33258-positive cells. Data (mean ± SEM) is
presented as multiple of untransfected control cells (UT, dotted line). Statistical significance versus AAstop cmRNA was assessed by two-way ANOVA adjusted for multiple
comparisons, with **p < 0.01, ****p < 0.0001, and n = 3.
Molecular Therapy: Methods & Clinical Developmentisolated rat liver ribosomes already 15 min after treatment with the
A-chain of the protein abrin-a. Previous studies demonstrated that
inhibition of protein synthesis is the main reason for abrin-a-induced
cell death.43
At low doses (9,100 molecules AA cmRNA per cell), translation of
EGFP cmRNA was inhibited substantially, while cell death was only
detected at higher doses. This discrepancy indicates that higher
amounts of AA are needed to disturb protein metabolism to such
an extent that it results in cell death. Furthermore, it has been
assumed that abrin-a can induce cell death independent of inhibition
of protein synthesis.45,46 Potentially, higher concentrations of abrin-a
are necessary for this toxicity-enhancing effect. In accordance with
what has been reported by different groups,45,47 this study demon-
strates that abrin-a induces apoptotic cell death. Caspase-3 activation
has been shown to be a key component of abrin induced apoptosis
with peak activation ranging from 18 hr to 48 hr.47,48 Cells undergo-
ing apoptosis bind to Annexin V but are impermeable to PI.49 Qu and
Qing45 showed Annexin V-positive but PI-negative cells at 8–36 hr
post-treatment with abrin, while at 40 hr themajority of cells was pos-146 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchitive for Annexin V and PI. They also detected DNA fragmentation
15 hr after exposure of cells to abrin, as was likewise shown by other
groups at 12 hr and 24 hr.47,50 After staining with Hoechst, chromatin
condensation has been observed in previous studies.45 While it is es-
tablished that cells treated with abrin-a undergo apoptosis, different
pathways have been proposed. Qu and Qing45 suggest that the inhi-
bition of protein synthesis and mitochondrial membrane damage
after reactive oxygen species (ROS) production present two indepen-
dent pathways. The intrinsic mitochondrial pathway has been
conﬁrmed by various groups.47,50 Saxena et al.48 showed the involve-
ment of the Fas ligand and thereby of the extrinsic pathway after
exposure to abrin.
In this study, besides toxicity in vitro, tumor growth in mice could be
diminished considerably by four intratumoral injections of 10 mg
formulated AA cmRNA. Twelve days after start of the treatment, the
volume of tumors treated with AA-LF132 was signiﬁcantly reduced
by 89% compared to tumors that had been injected with AAstop-
LF132. In comparison, a previous study using plasmid DNA coding
for the A-chain of diphtheria toxin under a target-cell-speciﬁc2018
Figure 6. Decrease in Cell Viability by AA-LF132 In Vitro and Its Influence on Tumor Growth In Vivo
(A and B) In vitro assessment of toxicity on KB cells at 48 hr post-transfection with AA-LF132, AAstop-LF132, or treatment with 2% sucrose (vehicle control).
(A) Representative pictures of KB cells transfected with 100 ng cmRNA. (B) CellTiter-Glo Luminescence Viability Assay. Cell viability was proportional to the measured
luminescence. Data is presented as mean in % ± SEM of untransfected control cells (UT, dotted line). Statistical significance versus AAstop-LF132 was assessed by
two-way ANOVA adjusted for multiple comparisons, with ****p < 0.0001 and n = 3. (C) Luciferase activity. 5  106 KB cells were injected into the flank of immuno-deficient
NMRI-numice. 10 mg of lipid nanoparticle formulated cmRNA coding for firefly luciferase was injected intratumorally on days 9, 11, and 13 after injection of tumor cells. On day
14, bioluminescence was determined. (D and E) In vivo anti-tumor activity of AA-LF132. 5  106 KB cells were injected into the flank of immuno-deficient NMRI-nu mice.
10 mg of AA-LF132, 10 mg of AAstop-LF132 or 2% sucrose were injected intratumorally on days 9, 11, 13, and 18 after injection of tumor cells. (D) Tumor volume was
measured in vivo throughout the experiment using a caliper. Arrows display days of treatment. Data represent means ± SEM (left) or individual values of eachmouse. n = 7 for
AA-LF132; n = 10 for AAstop-LF132 and 2% sucrose. (E) Tumor volume was determined ex vivo on day 21 after injection of tumor cells. Data represent means ± SEM.
Statistical significance was assessed by Kruskal-Wallis test adjusted for multiple comparisons, with *p < 0.05, ***p < 0.001, n = 7 for AA-LF132, n = 10 for AAstop-LF132 and
2% sucrose.
www.moleculartherapy.orgpromoter could diminish tumor size by 68% compared to the luc-ex-
pressing control plasmid group.51 To achieve these effects, three injec-
tions, each with 25 mg plasmid, were employed. Ramnath et al.52
showed a reduction in tumor volume in mice up to 62% comparedMoleculto the control group after ﬁve intralesional treatments with the protein
abrin-a. Another group could show that by single injection of an
immunotoxin containing the A-chain of abrin-a, tumor growth in
mice could be delayed by 7 to 10 days.28ar Therapy: Methods & Clinical Development Vol. 8 March 2018 147
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which comprises intratumoral co-administration of a toxin-encoding
mRNA with an immune-stimulatory agent analogous to the employ-
ment of armed oncolytic viruses.53 Their anti-tumor potency could be
extensively enhanced by inclusion of chemokines, cytokines or
tumor-associated antigens.54 Due to its immunological properties,
the mRNA molecule itself might serve as adjuvant.55 Conceivably,
this approach could be pursued prior to surgical removal of a primary
tumor with the aim of inducing tumor shrinkage and a systemic im-
mune response to disseminated tumor cells. Besides direct activation
of the immune system, blockage of molecules inhibiting T cell differ-
entiation or function, e.g. PD-1, displays a promising tool for stimu-
lation of the immune system.56
The present study clearly showed that cmRNA encoding for the
A-chain of abrin-a toxin displays effective anti-tumor properties.
By repeated injections of complexed cmRNA into tumors in mice, tu-
mor growth could be constrained in amanner comparable to previous
in vivo studies applying abrin-a or toxin-encoding plasmids. The
employment of mRNA is very attractive, as it shows various safety-
relevant beneﬁts compared to pDNA and limited toxicity has been
associated with immunotoxins. The promising results obtained with
AA prompt further studies using different tumor models to fully
appreciate the anti-tumor efﬁcacies of toxin encoding cmRNAs.
MATERIALS AND METHODS
Plasmid Preparation
The toxin (SubA, DTA, AA) and control (SubAstop, DTAstop,
AAstop) sequences were cloned at the KpnI site (Thermo Fisher,
Waltham, MA) into the backbone pVAX1-A120.24 Toxin and control
sequences codon optimized for expression inHomo sapienswere pro-
duced by GeneArt in two parts. Sequences were retrieved from NCBI
GenBank (SubA, AF399919.3; DTA, K01722.1; AA, AY458627.1).
Only the A-chain of the toxins was utilized. Subsequent sub-cloning
into pVAX1-A120 was performed using the GeneArt Seamless Clon-
ing and Assembly Enzyme Mix (Invitrogen, Darmstadt, Germany)
and One Shot TOP10 Chemically Competent E. coli (Invitrogen,
Darmstadt, Germany).
Generation of cmRNA
DNA plasmids were linearized downstream of the poly(A) tail with
the restriction enzyme NotI (Thermo Fisher, Waltham, MA), and
puriﬁcation was performed by chloroform extraction and ethanol
precipitation. The linearized plasmids were used as template for
in vitro transcription (IVT). IVT-mix was as follows: 0.1 mg/mL
plasmid, transcription buffer 1 (Ethris, Planegg, Germany), 1 U/mL
RiboLock Rnase Inhibitor (Thermo Fisher, Waltham, MA),
0.015 U/mL Inorganic Pyrophosphatase 1 (Thermo Fisher, Waltham,
MA), 2 U/mL T7 Polymerase (Thermo Fisher, Waltham, MA),
7.5 mM rATP, 7.5 mM rGTP, 5.6 mM rCTP, 5.6 mM rUTP,
1.9 mM 50-methyl-rCTP, and 1.9 mM 20-thio-rUTP. The nucleotides
were purchased from Jena Biosciences (Jena, Germany). The com-
plete IVT-mix was incubated at 37C for 4.5 hr, following which
1 U/mL DNase I (Thermo Fisher, Waltham, MA) was added to re-148 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchmove the plasmid template and the reaction incubated an additional
25 min at 37C. RNA was precipitated with ammonium acetate at a
ﬁnal concentration of 2.5 mM and washed twice with 70% ethanol
before it was re-suspended in aqua ad injectabilia. RNA concentra-
tion was measured on a spectrophotometric device (Nanodrop) and
its correct size and purity determined with 1% agarose gel and
RiboRuler High Range RNA Ladder (Thermo Fisher, Waltham,
MA). For subsequent capping, cmRNA was employed at a ﬁnal
concentration of 1 mg/mL and denaturated in advance at 65C for
15 min. The capping reaction mix contained 1 capping buffer
(NEB, Frankfurt, Germany), 0.5 mM GTP (NEB, Frankfurt, Ger-
many), 0.2 mM S-Methyladenosine (NEB, Frankfurt, Germany),
0.5 U/mL Vaccinia Virus Capping Enzyme (NEB, Frankfurt, Ger-
many), 2.5 U/mL mRNA Cap 20-o-Methyltransferase (NEB, Frank-
furt, Germany), and 1 U/mL RiboLock RNase Inhibitor (Thermo
Fisher, Waltham, MA). Reaction mix was incubated at 37C for
60 min before the RNA was precipitated with ammonium acetate at
a ﬁnal concentration of 2.5 mM and washed twice with 70% ethanol
before it was re-suspended in aqua ad injectabilia.
Cell-free Protein Synthesis System
In order to determine protein synthesis of luciferase ﬁreﬂy from luc
cmRNA (kindly provided by Ethris, Planegg, Germany) in a cell-
free system, the Rabbit Reticulocyte Lysate System (Promega, Madi-
son, WI) was applied according to the manufacturer’s instructions.
Per reaction of 35 mL lysate, 1 mg luc cmRNA and either 0.1 mg AA
or 0.1 mg AAstop cmRNA were employed simultaneously. After an
incubation of 45 min at 30C, luminescence was measured using Te-
can InﬁniteR 200 PRO (Tecan, Männedorf, Switzerland).
Cell Culture
Cells were maintained in a humidiﬁed incubator at 37C and 5%CO2.
HuH7 cells (CSC-C9441L, Creative Bioarray, Shirley, NY) were
cultured in DMEM (1) + GlutaMax supplemented with 10% fetal
bovine serum (FBS) and 1% Pen/Strep. For KB cells (ACC-136,
German Collection of Microorganisms and Cell Cultures [DSMZ],
Braunschweig, Germany), RPMI1640 (1) + GlutaMax supple-
mented with 10% FBS and 1% Pen/Strep was used as culture medium.
Both cell lines were authenticated by DSMZ.
Transfections in Cell Culture
If not stated otherwise, transfections were performed with Lipofect-
amine 2000 (Invitrogen, Darmstadt, Germany) according to the
manufacturer’s instructions using 2 mL Lipofectamine 2000 per mg
mRNA in medium without additives. Transfections were performed
in 96-well plates and 100 mL ﬁnal volume of medium per well, unless
speciﬁed differently. 1  104 KB cells and 3  103 Huh7 cells per
100mLmediumwere used in all in vitro experiments but for thewestern
blot,where 2 104 cells per 100mLmediumwere applied. For co-trans-
fections, 50 ng/100 mL of EGFP cmRNA (kindly provided by Ethris,
Planegg, Germany) and either 5, 0.05, or 0.0005 ng/100 mL of AA or
AAstop cmRNAs were transfected. For western blot detection, 40
and 80 ng/100 mL of AA or AAstop cmRNAwere used for transfection.
In all other experiments, 10 ng, 50 ng, or 100 ng ofmRNAwere applied2018
www.moleculartherapy.orgin a ﬁnal volume of 100 mL. At 4 hr after transfection, mediumwas dis-
carded, and supplemented cell culture medium was added. For in vivo
purposes, cmRNAs (AA and AAstop) were formulated using Ethris’
(Planegg, Germany) proprietary cationic lipid formulation LF132,
which was based on Jarzebinska et al.57 In order to examine their effec-
tiveness in vitro, cellswere transfectedwith 10, 50, and100ng/100mLof
AA-LF132 or AAstop-LF132. As vehicle control, 2% sucrose (diluted
accordingly) was applied. Just like with transfections using Lipofect-
amine 2000, at 4 hr after transfection medium was discarded and sup-
plemented cell culture medium added.
Cell Culture Assays
For all assays, luminescence was measured using Tecan InﬁniteR 200
PRO (Tecan, Männedorf, Switzerland). The Attune NxT (Thermo
Fisher, Waltham, MA) was employed for ﬂow cytometery analysis.
Microscopic images were taken with Leica DMi8 (Leica, Wetzlar,
Germany). Except for the western blot analysis (two independent
technical replicates), all cell culture assays were performed in three in-
dependent biological replicates, each treatment in triplicates.
SDS-PAGE and Western Blot
For western blot detection, cells were seeded in 6-well plates. The
assay was conducted 24 hr post-transfection. After washing the cells
with cold PBS, they were detached from the well using cell scrapers
and lysed in lysis buffer (25 mM Tris-HCl, 0.1% Triton X-100 [pH:
7.8], 1 cOmplete protease inhibitor [Sigma Aldrich, Steinheim, Ger-
many], 150 U/mL DNase I [Thermo Fisher, Waltham, MA]) for
30 min on ice. Total protein content was determined by the bicincho-
ninic acid (BCA) assay, following the manufacturer’s instructions
(Thermo Fisher, Waltham, MA). Cell lysates (45 mg of total protein
per sample) were separated on 4%–12% polyacrylamide gels (Thermo
Fisher, Waltham, MA) and transferred to polyvinylidene ﬂuoride
(PVDF) membranes (Bio-Rad). Membranes were blocked inWestern
Breeze blocking solution (Thermo Fisher, Waltham, MA) and probed
with antibodies against abrin-a (6.7 mg/mL, Tetracore, Rockville,
MD) and vinculin (1:10,000, Abcam, Cambridge, UK). For protein
detection, horseradish peroxidase (HRP)-conjugated anti-rabbit
(1:10,000, sc2004; Santa Cruz Biotechnology, Dallas, TX) antibodies
were added. For signal detection, Luminata Western HRP substrate
was applied according to the manufacturer’s protocol (Merck Chem-
icals, Darmstadt, Germany).
Protein Synthesis Inhibition
To determine EGFP expression 24 hr post-transfection, culture me-
dium was put aside, cells trypsinized with TrypLE Express Enzyme
(Thermo Fisher, Waltham, MA), re-suspended in the cell culture me-
dium, and analyzed by ﬂow cytometry. Analysis was performed on
singlet cells.
Cell Viability/Toxicity Assays
Assays were conducted 48 hr post-transfection. To determine cell
viability, the CellTiter-Glo Luminescent Cell Viability Assay (Prom-
ega, Madison, WI) was performed according to the manufacturer’s
instruction. Before addition of the substrate, the plate was centrifugedMoleculfor 5 min at 1,100 rpm, the medium discarded, and fresh supple-
mented medium added. For dead cell staining, culture medium was
put aside, and cells were trypsinized with TrypLE Express Enzyme
(Thermo Fisher, Waltham, MA) and re-suspended in the cell culture
medium. PBS containing 5 mg/mL PI (Sigma Aldrich, Steinheim, Ger-
many) was added at 1:5 (v/v) to the cell suspension before analysis
with ﬂow cytometry. Analysis was performed on singlet cells.
Apoptotic Assays
Annexin V-PI double staining was performed 24 hr post-transfection.
Annexin V, Alexa Fluor 488 conjugate (Thermo Fisher, Waltham,
MA) was used according to the manufacturer’s instruction, and PI so-
lution (Sigma Aldrich, Steinheim Germany) was applied at 1 mg/mL.
Analysis was performed on singlet cells. For this assay, 24-well plates,
containing 4 104 cells per well in a ﬁnal volume of 400 mL medium,
were used. Activity of caspases-3 and -7 was assessed 24 hr post-trans-
fection with the Caspase-Glo 3/7 Assay (Promega, Madison, WI) ac-
cording to the manufacturer’s instruction. At 48 hr post-transfection,
Hoechst33258 (Thermo Fisher, Waltham, MA) was employed at
10 mg/mL in supplemented cell culture medium and cells incubated
for 15 min at room temperature. Before examination, Hoechst33258
was discarded, and fresh supplemented cell culture medium was
added. Of each replicate, nine images at 20 magniﬁcation were
taken, and the number of Hoechst33258-positive cells was counted.
Expression of Firefly Luciferase in the Tumor and Reduction of
Tumor Growth in Mice
5  106 KB cells were injected into the ﬂank of female, 6-week-old
NMRI-nu mice (RjOrl:NMRI-Foxn1nu /Foxn1nu, Janvier Labs, Saint
Berthevin Cedex, France). For the pre-experiment, 10 mg cmRNA cod-
ing for ﬁreﬂy luciferase (kindly provided by Ethris, Planegg, Germany)
in 50 mL 2% sucrose was injected into the formed tumors on days 9, 11,
and 13 after injection of tumor cells. Twenty-four hours after the third
application, luminescence was measured using an IVIS In Vivo Imag-
ing System with Living Image software 3.2 (Caliper Life Sciences,
Mountain View, CA). 100 ml luciferin (60 mg/mL in PBS) were in-
jected intraperitoneally 15 min prior to imaging. For the reduction
of tumor growth, the cmRNAs (AA and AAstop) were formulated
in a proprietary lipid formulation (LF132) by Ethris (Planegg, Ger-
many) in 2% sucrose (Sigma Aldrich, Steinheim, Germany). The
cationic lipid formulation LF132 was based on Jarzebinska et al.57
Treatment was started as soon as tumors had reached a sufﬁcient
size (100 mm3, day 9). 50 ml of solution containing either 10 mg of
AA-LF132, 10 mg of AAstop-LF132 or 2% sucrose were injected intra-
tumorally on days 9, 11, 13, and 18 post-injection of tumor cells.
Throughout the experiment, tumor volume was determined with a
caliper using the formula a  b2/2, with a indicating the length of
the tumor and b the width. On day 21 after injection of tumor cells,
mice were euthanized by cervical dislocation. Tumor was explanted,
and tumor size was measured again using the formula a  b  c/2.
The protocols for animal experiments were approved by the animal
ethics committee and the government of Oberbayern (May 26, 2014;
Permit Number, Az. 55.2-1-54-2531-53-09), and experiments were
executed in accordance with the German Animal Welfare Law.ar Therapy: Methods & Clinical Development Vol. 8 March 2018 149
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Flow cytometry data was analyzed by FlowJo v.10.0.8 (FlowJo, Ash-
land, OR). GraphPad Prism 6 (GraphPad Software, La Jolla, CA)
was utilized for statistical analysis.
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